A CD&D

Abbot Laboratories (Abbott Park, Illinois) treceived CE mark approval for a 2.25 mm version of its XIENCE V Everolimus Eluting Coronary Stent System, offering a smaller stent for a wider range of stent sizes for treating a variety of patient types.

"Lesions in small vessels tend to be more complex and challenging to treat, so it's important to have a drug eluting stent with proven clinical benefits that can be easily delivered to the diseased area of the vessel," said Charles Simonton, MD, divisional VP, Medical Affairs and chief medical officer, Abbott Vascular.

The 2.25 mm version of the XIENCE V will be launched immediately in the majority of European markets and select countries in Asia and Latin America. The XIENCE V also is available in diameters of 2.5 mm, 2.75 mm, 3.0 mm, 3.5 mm and 4.0 mm for lesions 28 mm or shorter.

XIENCE V was launched in Europe and other international markets in late 2006. XIENCE V is an investigational device in the U.S. and Japan, and is under review for approval by the FDA.